Takeda and Roivant launch Myovant; Takeda grants rights
Takeda Pharmaceutical Co. Ltd. and Roivant Sciences Ltd. together launched Myovant Sciences Ltd., a new biotech operating as a Roivant subsidiary that will be focused on therapies for women's health conditions and prostate cancer.
- Specialty Pharmaceuticals
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.